Bionure has successfully concluded its Phase 1 clinical study with its lead compound, BN201. The study was aimed at investigating safety, tolerability and pharmacokinetics of single and multiple doses of BN201.Bionure’s initial focus areas are Acute Optic Neuritis (AON) and Multiple sclerosis (MS), for which there still are high unmet medical needs. The mechanism of action of BN201 will enable it to ideally address further indications relevant for a neuroprotective agent, including other neurodegenerative disorders, cerebrovascular disease, certain ophthalmic diseases and traumatic central nervous system injuries.
 
“I’m delighted about the results of the Phase 1 clinical study that is a clear milestone achievement following our 15 years of research in neuroprotection. We will now prepare the implementation of a Phase 2 program to confirm the potential of BN201 to bring clinical benefits to patients,” said Dr. Pablo Villoslada, scientific founder and CSO of Bionure.
 
“Currently there is a strong need for effective neuroprotectants and no remyelinating drug approved. Since only a handful of programs are in clinical development, this represents a great opportunity for Bionure to become a game changer in the neuroprotective market. We will now prepare a Series B financing round to fund the Phase 2 program,” added Laurent Nguyen, CEO of Bionure.
 
BN201 is covered by Composition of Matter and Method-of-Use patents and has orphan drug designation in the EU and the US for Acute Optic Neuritis.